The Capacity Paradox

The Pipeline Doesn’t Wait for Capacity

The global restructuring that preceded this moment was, by external measures, a success: a $1 billion cost program that stabilized margins and positioned the company to absorb a $5.6 billion acquisition. By the metrics that move equity markets, the “Fit for Growth” program worked.

The problem surfaces one level down — at the affiliate.

Biogen Canada is the entity asked to execute the strategy that global restructuring was designed to enable. And it is doing so with a structurally reduced headcount, across seven active product files in five therapeutic areas, at the exact moment when Canada’s regulatory and reimbursement environment has become measurably more demanding.

SKYCLARYS entered active pCPA negotiation in August 2025 with the hardest possible starting position: a split recommendation. CDA-AMC issued a positive recommendation for the Rest of Canada (ROC); INESSS issued a negative one for Quebec — the province with the highest density of Friedreich’s ataxia patients in the country. Any concession sufficient to rescue the Quebec listing risks triggering most-favoured-nation clauses across the ROC agreement. There is no clean path through this without the right people in the same room.

QALSODY crossed into active pCPA negotiation in March 2026, serving a national patient population estimated at 40 individuals at a first-year cost approaching $430,000 per patient. The negotiation is not primarily a pricing problem — it is an infrastructure problem. Monthly intrathecal lumbar punctures require trained clinicians, procedural suite time, and standardized biomarker reporting across fragmented provincial labs. None of that infrastructure exists yet. If Biogen waits for the Letter of Intent before designing it, provincial listings will stall at the hospital level before the first patient is treated.

ZURZUVAE received its Notice of Compliance in December 2025, then immediately hit a regulatory wall. A CDSA scheduling process triggered by zuranolone’s mechanism has suspended commercial readiness across the entire launch infrastructure — supply chain, specialty pharmacy, private payer, and field force — with no date certain on the other side.

A New Therapeutic Area — and a More Complex Problem

The Apellis situation is structurally different from the pipeline challenges above: it is not a market access problem waiting on a regulatory trigger. It is an integration problem with a financial clock already running.

Among the assets inherited: SYFOVRE, the first globally approved therapy for geographic atrophy secondary to AMD, whose Canadian New Drug Submission was cancelled by Health Canada in January 2025 after data deficiencies were identified. Biogen Canada is not inheriting a launch. It is inheriting a retracted regulatory dossier in ophthalmology — a therapeutic area where it has no commercial infrastructure, no KOL relationships, and no institutional memory. A resubmission requires rebuilding credibility with Health Canada and the Canadian Retina Society simultaneously, using five-year GALE extension data that demonstrates meaningful lesion progression delay, while managing post-marketing safety signals around retinal vasculitis that have complicated the global clinical narrative.

The financial structure compounds the pressure. The deal includes a contingent value right — a performance-based payment to Apellis shareholders triggered only if SYFOVRE hits specific global net sales thresholds starting in 2027. Every month of Canadian delay is a direct liability against those commitments. The BMS/Celgene acquisition offers the relevant precedent: in 2019, BMS structured a similar instrument around pipeline approval deadlines, then missed one by 36 days due to manufacturing and regulatory coordination failures. A $6.4 billion payout expired worthless. The mechanism that makes these instruments attractive to sellers is the same one that creates misaligned incentives inside the acquiring organization — legacy Apellis teams are incentivized to push for maximum sales velocity while regional affiliates absorb a new therapeutic area without commensurate resources.

Which points to the risk the financial structure doesn’t capture: the people. Biogen’s CEO has stated explicitly that the company is acquiring Apellis in part to absorb its ophthalmology commercial capabilities and its nephrology infrastructure — the latter intended to support the commercial launch of felzartamab, which arrived through a separate $1.15 billion acquisition of Human Immunology Biosciences. If the Apellis commercial teams depart before the integration is complete, Biogen loses the platform it needs to launch an asset it acquired through an entirely different transaction.

The Structural Problem Beneath the Pipeline

Each of these challenges — SKYCLARYS, QALSODY, ZURZUVAE, SYFOVRE, and the remaining files building behind them in nephrology, Alzheimer’s, and immunology — shares a structural root cause.

In each of these files, the clinical evidence exists. The regulatory pathway is visible. The commercial rationale is clear. What doesn’t exist is a mechanism for the people who control different parts of the path — pCPA negotiators, INESSS reviewers, provincial drug plan directors, hospital administrators, clinical specialists, patient advocates — to reach a binding commitment together. They engage sequentially, through separate channels, without shared visibility into each other’s constraints. That is why files stall. Not for lack of analysis. For lack of a room.

Why Conventional Approaches Won’t Close the Gap

Why Process Is the Variable That Matters

The common thread across these files is not a shortage of data or expertise. Biogen Canada has the clinical evidence, the regulatory experience, and the analytical capability. What the organization is missing — across all eight files simultaneously, with a structurally reduced headcount — is a mechanism for producing committed decisions in systems where no single actor controls the whole path. That is a process problem. And process problems have process solutions.

When the stakes are high, most life sciences leaders reach for more analysis: expert advisory boards, consultant reports, rigorous dossiers. The research on this pattern is consistent and uncomfortable: how you decide matters more than what you analyze.

The implication for a pipeline of this complexity is direct: more data and more analysis will not close the coordination gap. A deliberately designed process — one that brings the right actors into the same room, with the right framing, at the right moment — is what converts strategic clarity into committed action.

Eight Challenges. One Structural Root Cause.

Each of the following challenges was identified through MMG’s independent research as a file where execution is stalled — either because a regulatory trigger has not yet cleared, because the infrastructure required to act doesn’t exist yet, or because the actors who must move hold conflicting incentives with no standing forum to produce a binding commitment. In most cases, all three are true simultaneously.

What Structured Convening Delivers

A Mind Meeting is an intensive 3-day solving sprint designed specifically for challenges where progress depends on the simultaneous commitment of actors who sit outside any single organization’s authority. It is not an advisory board, a conference, or a facilitated workshop in the conventional sense. It is built around a specific challenge — one where the actors who must move hold conflicting incentives, where no standing forum exists to produce a binding outcome, and where standard execution tools have already reached their limits. For Biogen Canada, every challenge on this page meets that description.

The preparation phase identifies which actors must be in the room, how the challenge must be framed to make productive deliberation possible, and what decisions need to emerge by the end of the session. MMG facilitates the session itself — managing the dynamics that cause multi-stakeholder deliberations to collapse into consensus theater rather than committed decisions — and structures the follow-through that translates outcomes into accountable next steps. Who gets invited, and in what role, is determined by a single criterion: who controls the part of the path that everyone else is waiting on.

What a client organization leaves with is specific: a committed decision, a clear allocation of responsibility across actors, and a defined condition for reconvening if the environment changes. No open questions that reset the conversation. No advisory outputs that require a second round of internal approval before anything moves. For Biogen Canada, where coordination delays translate directly into months of patient access lost, negotiation leverage eroded, and CVR milestone pressure compounded, that specificity is not a feature of the process. It is the purpose of it.

Depending on the specific challenge and where key actors are located, Mind Meeting workshops are designed to be held in-person, virtually, or in a hybrid format. For files where the quality of deliberation depends on the dynamics of a shared physical room — complex negotiations, high-stakes alignment sessions with significant relationship friction — we recommend an in-person format. For files where geographic distribution of stakeholders is the binding constraint, a structured virtual session can achieve the same decision-grade outcomes. The format is a design decision, not a default.

How MMG Compares

Book a Discovery Call

More data will not close the gap Biogen Canada is navigating. More stakeholder meetings, run one at a time, will not produce the committed coordination that eight simultaneous priority files require. What converts strategic clarity into committed action is a deliberately designed process — one that brings the right actors into the same room, with the right framing, at the right moment.

That is what Mind Meeting Group builds. To learn more, book a discovery call with Mark McCarvill at the link below.